Immediate effect of benzalkonium chloride in decongestant nasal spray on the human nasal mucosal temperature.
Benzalkonium chloride is a preservative commonly used in nasal decongestant sprays. It has been suggested that benzalkonium chloride may be harmful to the nasal mucosa. Decongestion with the vasoconstrictor xylometazoline containing benzalkonium chloride has been shown to cause a significant reduction of the nasal mucosal temperature. The purpose of the present study was to determine the short-term influence of xylometazoline nasal spray with and without benzalkonium chloride on the nasal mucosal temperature. Healthy volunteers (30) were included in the study. Fifteen volunteers received xylometazoline nasal spray (1.0 mg/mL) containing benzalkonium chloride (0.1 mg/mL) and 15 age-matched subjects, received xylometazoline nasal spray without benzalkonium chloride. Using a miniaturized thermocouple the septal mucosal temperature was continuously measured at defined intranasal detection sites before and after application of the nasal spray. The mucosal temperature values did not significantly differ between the group receiving xylometazoline containing benzalkonium chloride and the group receiving xylometazoline spray without benzalkonium chloride before and after decongestion (P > 0.05). In both study groups septal mucosal temperatures significantly decreased after decongestion (P < 0.05) because of a reduction of the nasal mucosal blood flow following vasoconstriction. This study indicates that benzalkonium chloride itself does not seem to influence nasal blood flow and nasal mucosal temperature in topical nasal decongestants.
Lindemann
J
J
Department of Otorhinolaryngology, University of Ulm, Ulm, Germany. joerg.lindemann@medizin.uni-ulm.de
Leiacker
R
R
Wiesmiller
K
K
Rettinger
G
G
Keck
T
T
D000280:Administration, Inhalation; D000293:Adolescent; D000328:Adult; D000336:Aerosols; D001548:Benzalkonium Compounds / Q000008:administration & dosage / Q000494:pharmacology*; D001831:Body Temperature / Q000187:drug effects*; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000494:pharmacology; D008297:Male; D014663:Nasal Decongestants / Q000008:administration & dosage / Q000494:pharmacology*; D009297:Nasal Mucosa / Q000098:blood supply / Q000187:drug effects*; D012039:Regional Blood Flow / Q000187:drug effects
D000336:Aerosols; D001548:Benzalkonium Compounds; D007093:Imidazoles; D014663:Nasal Decongestants; C009695:xylometazoline